Veradermics, Inc Debt Securities, Available-for-sale, Unrealized Loss Position
Veradermics, Inc (MANE) had Debt Securities, Available-for-sale, Unrealized Loss Position of $590.70 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $590.70M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $267.40M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $9.60M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $590.70M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $267.40M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $9.60M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |